Cargando…

Diagnosis and Management of Pembrolizumab-Associated Pericardial Effusion in a Non-small Cell Lung Cancer Patient

The advent of immune checkpoint inhibitors (ICIs) in the field of oncology has improved the outcome response rate for a variety of neoplastic pathologies with improved cellular specificity that lacks the traditional adverse effects associated with chemotherapy. However, ICIs are not without adverse...

Descripción completa

Detalles Bibliográficos
Autores principales: Pollock, James, Castillo, Elquis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183094/
https://www.ncbi.nlm.nih.gov/pubmed/37193471
http://dx.doi.org/10.7759/cureus.37556

Ejemplares similares